Multicenter iTBS Neuromodulation for PTSD Treatment
Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · May 23, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for people with Posttraumatic Stress Disorder (PTSD) using a method called intermittent theta-burst transcranial magnetic stimulation (iTBS). This technique involves using magnetic fields to stimulate a part of the brain called the primary motor cortex, which may help reduce the symptoms of PTSD. The researchers want to see if this treatment can help improve not only PTSD symptoms but also mood, quality of life, and overall social and work functioning.
To participate in the trial, you need to be between 18 and 65 years old, right-handed, and have a diagnosis of PTSD that meets specific criteria. It's important that you've been stable on your current medications for at least four weeks. However, there are some exclusions; for example, you cannot have a history of certain serious medical conditions or mental health disorders. If you join the study, you can expect to receive the iTBS treatment and be monitored for any changes in your symptoms and overall well-being. This trial is currently recruiting participants, so if you or someone you know might be interested, it could be a valuable opportunity to explore a new option for managing PTSD.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged between 18 to 65 years old
- • Right handedness
- • Have a diagnosis of PTSD meeting DSM-5 criteria
- • CAPS-5 score\>35
- • Under stable medication for at least four weeks
- • Capable of independently reading and understanding study materials and providing informed consent.
- Exclusion Criteria:
- • Current (or past if appropriate) significant neurological or medical disorder, or lifetime history of 1) seizure disorder; 2) primary or secondary CNS tumors; 3) stroke; or 4) cerebral aneurysm.
- • Primary psychotic disorder, bipolar I disorder, major depressive disorder, or personality disorders
- • Lifetime history of attempted suicide or HAMD-17 suicide item (item 3) ≥ 3 points
- • Implanted device (deep brain stimulation) or metal in the brain; a pacemaker, extensive dental work, or any magnetic metal implants and upper body tattoos if choose to do fMRI
- • Previous experience of rTMS
- • Pregnancy/lactation, or planning to become pregnant during the study
- • Current under psychological or other physical treatments
About Second Affiliated Hospital, School Of Medicine, Zhejiang University
The Second Affiliated Hospital of Zhejiang University School of Medicine is a leading clinical research institution dedicated to advancing healthcare through innovative medical practices and rigorous scientific inquiry. With a robust infrastructure and a multidisciplinary team of experienced researchers and clinicians, the hospital is committed to conducting high-quality clinical trials that address critical health challenges. As an integral part of Zhejiang University, the hospital leverages academic expertise and cutting-edge technology to foster collaboration in research, education, and patient care, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Hangzhou, Zhejiang, China
Hangzhou, Zhejiang, China
Ningbo, Zhejiang, China
Patients applied
Trial Officials
Yuan Shen, M.D., Ph.D.
Principal Investigator
Shanghai Mental Health Center
Chang Yu, M.D.
Principal Investigator
The Affiliated Kangning Hospital of Ningbo University
Kai Wang, M.D., Ph.D.
Principal Investigator
The First Affiliated Hospital of Anhui Medical University
Xiaoming Li, M.D., Ph.D.
Principal Investigator
Second Affiliated Hospital, School of Medicine, Zhejiang University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported